Eli Lilly & Company (NYSE:LLY) ranks among the most active stocks to buy according to Wall Street analysts. Following favorable Phase 3 trial findings for Eli Lilly & Company (NYSE:LLY)’s obesity treatment, UBS reaffirmed its Buy rating and $895 price target on the company on August 27. The pharmaceutical company revealed topline results from its ATTAIN-2 trial examining orforglipron in individuals with obesity and type 2 diabetes. According to UBS, the data is “a clear positive,” with orforglipron demon ...